AGLE - Aeglea surges 40% following additional phase 3 data for pegzilarginase for rare disorder

Additional data from a phase 3 trial of Aeglea BioTherapuetics' (NASDAQ:AGLE) pegzilarginase for the rare inherited metabolic disorder Arginase 1 Deficiency (ARG1-D) sent shares surging 40% in after-hours trading. In a patient-level outcomes analysis, 11 patients (65%) receiving pegzilarginase reached or exceeded prespecified response criteria for at least one mobility assessment compared to four patients (44%) on placebo. Eight patients (47%) met or exceeded prespecified clinical response criteria for at least two of the mobility outcomes compared to none receiving placebo. Previously announced top-line results from December 2021 found that there was a 76.7% reduction in mean plasma arginine in pegzilarginase -treated patients compared to placebo, meeting the primary endpoint. Those living with ARG1-D can experience severe spasticity-related mobility limitations, seizures, developmental delay, intellectual disability, and early mortality. Seeking Alpha's Quant Rating gives Aeglea (AGLE) a strong sell rating.

For further details see:

Aeglea surges 40% following additional phase 3 data for pegzilarginase for rare disorder